Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ / shares in Thousands, $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Unrestricted cash and cash equivalents	$ 101,049	$ 60,968
Restricted cash and cash equivalents	65,184	80,786
Loans, interest and fees receivable, at fair value	5,394	6,306
Loans, interest and fees receivable, gross	562,472	541,344
Allowances for uncollectible loans, interest and fees receivable	(85,319)	(79,211)
Deferred revenue	(47,251)	(43,897)
Notes payable, at face value	$ 408,242	$ 390,927
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	15,977,130	15,563,574
Common stock, outstanding (in shares)	15,977,130	15,563,574
Own-share lending arrangement, outstanding (in shares)	1,459,233	1,459,233
Variable Interest Entity, Primary Beneficiary [Member]
Unrestricted cash and cash equivalents	$ 41,100	$ 16,800
Restricted cash and cash equivalents	45,700	61,000
Loans, interest and fees receivable, at fair value	4,800	5,700
Loans, interest and fees receivable, gross	453,100	403,400
Allowances for uncollectible loans, interest and fees receivable	(76,500)	(57,400)
Deferred revenue	(16,900)	(13,200)
Notes payable, at face value	$ 382,400	$ 366,700